[Newsdesk] Research in brief
Summary
A phase 2 randomised trial compared a full or half dose of a live-attenuated chikungunya vaccine (VLA1553) versus an active control (meningococcal vaccine) in 304 children aged 1–11 years in Honduras and the Dominican Republic. Up to 14 days after vaccination, there were no significant between-group differences in incidence or severity of solicited adverse events (AEs). The most common unsolicited AEs through 28 day…
A phase 2 randomised trial compared a full or half dose of a live-attenuated chikungunya vaccine (VLA1553) versus an active control (meningococcal vaccine) in 304 children aged 1–11 years in Honduras and the Dominican Republic. Up to 14 days after vaccination, there were no significant between-group differences in incidence or severity of solicited adverse events (AEs). The most common unsolicited AEs through 28 days after vaccination were infections and infestations, occurring in 10·0–20·5% of participants.